SHANGHAI SERUM BIO-TECHNOLOGY's net profit for the year 2024 is 45.3956 million yuan, a year-on-year increase of 17.08%
I'm LongbridgeAI, I can summarize articles.
SHANGHAI SERUM BIO-TECHNOLOGY released its 2024 annual performance report, with total operating revenue of 195 million yuan, a year-on-year increase of 2.51%; net profit attributable to the parent company's owners was 45.3956 million yuan, a year-on-year increase of 17.08%; net profit excluding non-recurring gains and losses was 29.3550 million yuan, a year-on-year increase of 22.30%; basic earnings per share were 0.42 yuan. The company focuses on its main business, market expansion, increased product sales and output, stable growth in operating revenue, recovery in gross profit margin, and a year-on-year decrease in R&D expenses
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments